CN109966349A - A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy - Google Patents
A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy Download PDFInfo
- Publication number
- CN109966349A CN109966349A CN201910407722.1A CN201910407722A CN109966349A CN 109966349 A CN109966349 A CN 109966349A CN 201910407722 A CN201910407722 A CN 201910407722A CN 109966349 A CN109966349 A CN 109966349A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- diabetic retinopathy
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The embodiment of the invention discloses a kind of Chinese medicine compositions and preparation method thereof for preventing and treating diabetic retinopathy, belong to technical field of traditional Chinese medicines.The Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of Herba Epimedii, 10-20 parts of the horsewhip tip, 10-15 parts of polyporus lucidus, 10-15 parts of wild chrysanthemum, small blood rise 10-15 parts, 10-15 parts of Cortex Eucommiae, 10-15 parts of semen plantaginis.The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the embodiment of the present invention has effects that supplementing qi and nourishing yin, cooling blood and hemostasis, activating microcirculation and removing stasis medicinal; hemorheological property can be improved; it promotes blood circulation; so as to improve the tissue impaired with reparation; compromised retinal is protected, diabetic retinopathy is made to be controlled effectively to a certain extent, delays the development of the state of an illness; and there is preferable safety, it is worth further clinical application research.
Description
Technical field
The present embodiments relate to technical field of traditional Chinese medicines, and in particular to a kind of Chinese medicine group for preventing and treating diabetic retinopathy
Close object and preparation method thereof.
Background technique
Diabetic retinopathy (DR) is that diabetes (diabetes mellitus, DM) most common capilary is concurrent
One of disease, according to statistics, if diabetic's illness 10 years, there may be 50% people to will appear the lesion of retina.Such as fruit disease
Journey is more than 25 years, may have the patient for reaching 90% diabetic retinopathy occur.Diabetic retinopathy is to lead to DM
The main reason for patient's vision declines, if being not treated in time, can cause irreversible visual function damage.
The symptom of patients with diabetic retinopathy:
1, aneurysms: being sign that diabetic retinopathy clinically more early occurs, more exact.Positioned at view
Film inner nuclear layer, roundlet is dotted, often first comes across eyeground Posterior pole, especially in macular area, is distributed in temporo side more.
2, inter-retinal hemorrhage: it is located at capillary vein end, retina deep layer, rounded dotted or flamboyancy.
3, hard exudate: it is located in retina between shape layer and inner nuclear layer.In wax yellow color dot, sheet, boundary is more clear
Chu.More typically in Posterior pole, aneurysms is contained at the center of hard exudate ring, when involving macula area, may occur in which large stretch of asterism spot,
The hard exudate of macula lutea is also the reason of seriously affecting eyesight.
4, macular edema: initial stage oedema further involves inner molecular layer and mind between external plexiform layer and inner nuclear layer
Through fibrous layer, retina holostrome is reached more afterwards.Clinical signs are that retina swelling thickens, and are in opaque appearance, macular edema table
It is now capsule sample, fluorescein angiographic can clearly show that.
After diabetic retinopathy is made a definite diagnosis by fluorescence fundus angiography, controlled according to the state of an illness using drug or laser
It treats.
1, glucose-lowering treatment: use diet control or joint hypoglycemic medicine by glycemic control in normal range (NR) as far as possible, when oral
Medicine cannot be such that hyperglycemia reduces, then need actively to instruct insulin injection according to endocrine doctor.
2, conservative medication: in addition to strict control diabetes, medicine is can be used in early stage (nonproliferative retinopathy type)
Object treatment.
3, the development of retinopathy can laser therapy: be prevented.
4, minimally invasive vitrectomy: minimally invasive vitrectomy is mainly used for the complication of proliferative retinopathy,
Operation purpose be to remove hematocele, cutting machine film, elimination fibr tissue to rely the bracket of growth, the drawing loosened to retina,
Silicone oil or gas are filled in vitreous chamber when necessary, restores normal retina anatomy relationship, the full view of row in operation or after operation
Nethike embrane light is solidifying.
Existing drug or laser therapy can treat diabetic retinopathy to a certain degree, but take medicine for a long time
Object, there are biggish toxic side effects, and there is also certain risks for operation, and are easy recurrent exerbation.
Chinese medicine makes some progress in treatment diabetic retinopathy, and sufficiently shows that the unique of traditional Chinese medicine treats
Effect and advantage.
Summary of the invention
For this purpose, the embodiment of the present invention provide it is a kind of prevent and treat diabetic retinopathy Chinese medicine composition and its preparation side
Method, the Chinese medicine composition is in terms of preventing and treating diabetic retinopathy, with curative for effect, toxic side effect is small, recurrence rate is low
Advantage.
Diabetic retinopathy category Chinese medicine " mesh disease of quenching one's thirst " scope, by traditional Chinese medical discrimination method, diabetes view
Film lesion simple phase and proliferation have no that hemostasis shows based on deficiency of both qi and yin early period, but eyeground and Hemorheology have changed,
When developing to stagnation of QI and blood, on the basis of retinal microcirculation is damaged extensively, retinal neovascularization is generated, is increased with fiber
Raw, retina anasarca and large stretch of bleeding form proliferation period vitreoretinopathy, have prompted to undermine with disease yin and reflect
Conversion, by the development of simple phase to proliferation period, blood stasis syndrome also aggravates therewith, illustrates blood stasis with diabetic retinopathy
Become entire occurrence and development process, the present invention is on the basis of above-mentioned theory, to the Chinese medicine composition of prevention and treatment diabetic retinopathy
Raw material and content have conducted extensive research, finally obtain the content of present invention.
To achieve the goals above, the embodiment of the present invention provides the following technical solutions:
According to a first aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of prevention and treatment diabetic retinopathy
Chinese medicine composition, the Chinese medicine composition is prepared from the following raw materials in parts by weight:
10-20 parts of Herba Epimedii, 10-20 parts of the horsewhip tip, 10-15 parts of polyporus lucidus, 10-15 parts of wild chrysanthemum, small blood rise 10-15
Part, 10-15 parts of Cortex Eucommiae, 10-15 parts of semen plantaginis.
Further, the Chinese medicine composition is prepared from the following raw materials in parts by weight:
18 parts of Herba Epimedii, 16 parts of the horsewhip tip, 13 parts of polyporus lucidus, 13 parts of wild chrysanthemum, small blood rise 12 parts, 12 parts of Cortex Eucommiae, Chinese herbaceous peony
12 parts of son.
According to a second aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of above-mentioned prevention and treatment diabetes views
The preparation method of the Chinese medicine composition of film lesion, the described method comprises the following steps:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4-6 times is measured water and decocted 1-2 hours, filter
It crosses, for the second time plus 2-4 times is measured water and decocted 0.5-1 hours, and filtration, twice decocting liquid merging staticly settles 18-24 hours, takes supernatant
Liquid, relative density is the clear cream of 1.15-1.25 when being concentrated under reduced pressure into 60 DEG C, is dried to dried cream powder.
According to a third aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of prevention and treatment diabetic retinopathy
Chinese materia medica preparation, Chinese materia medica preparation Chinese medicine composition as made from above-mentioned Chinese medicine composition or above-mentioned method and pharmaceutically
Acceptable auxiliary material is made.
Further, the preparation oral liquor, granule, tablet, any in capsule.
The embodiment of the present invention has the advantages that
The embodiment of the present invention prevention and treatment diabetic retinopathy Chinese medicine composition with Herba Epimedii, the horsewhip tip, polyporus lucidus,
Wild chrysanthemum, small blood rises, Cortex Eucommiae, semen plantaginis are raw material, wherein Herba Epimedii QI invigorating is reinforced the kidney, in the hope of it；The dispelling wind and eliminating dampness of the horsewhip tip,
Promoting blood circulation to remove blood stasis；Polyporus lucidus replenishing qi and blood, tranquilizing mind, strengthening the spleen and stomach；Wild chrysanthemum clearing heat and removing internal heat, clears liver and improve vision at antibacterial anti-inflammatory；Small blood, which is risen, dispels
Wind promoting blood circulation, removing toxicity for detumescence, hemostasis；Cortex Eucommiae tonifies the liver and kidney, strengthens muscles and bones；Tonify the liver and kidney, strengthen muscles and bones reducing fever and causing diuresis, excreting dampness is logical
Leaching.The above raw material compounding, has effects that supplementing qi and nourishing yin, cooling blood and hemostasis, activating microcirculation and removing stasis medicinal, can improve hemorheological property, promote
Blood circulation protects compromised retinal to repair impaired tissue, obtains diabetic retinopathy to a certain extent
To effective control, delay the development of the state of an illness.
The clinical effectiveness of the Chinese medicine composition of the prevention and treatment diabetic retinopathy of the embodiment of the present invention is better than simple oxybenzene
Sulfonic acid calcium capsule can be obviously improved patient's vision, promote fundus hemorrhage exudation to absorb, reduce eyeground microaneurysm, mitigate eye
Bottom lesion to be conducive to prevent and reduce the blinding of patient, disable, and has preferable safety, is worth further clinical
Application study.
Specific embodiment
Embodiments of the present invention are illustrated by particular specific embodiment below, those skilled in the art can be by this explanation
Content disclosed by book is understood other advantages and efficacy of the present invention easily, it is clear that described embodiment is the present invention one
Section Example, instead of all the embodiments.Based on the embodiments of the present invention, those of ordinary skill in the art are not doing
Every other embodiment obtained under the premise of creative work out, shall fall within the protection scope of the present invention.
Embodiment 1
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 16 grams of Herba Epimedii, 14 grams of the horsewhip tip,
10 grams of polyporus lucidus, 13 grams of wild chrysanthemum, small blood rise 10 grams, 13 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4 times of amount water decoct 2 hours, filtration, the
Secondary plus 2 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 18 hours, take supernatant, are concentrated under reduced pressure into 60
DEG C when relative density be 1.22 clear cream, be dried to dried cream powder.
Embodiment 2
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 18 grams of Herba Epimedii, 16 grams of the horsewhip tip,
13 grams of polyporus lucidus, 13 grams of wild chrysanthemum, small blood rise 12 grams, 12 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4.5 times of amount water decoct 1.5 hours, filter
It crosses, for the second time plus 3 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 18 hours, takes supernatant, reduced pressure
The clear cream that relative density is 1.18 when to 60 DEG C, is dried to dried cream powder.
Embodiment 3
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 20 grams of Herba Epimedii, 18 grams of the horsewhip tip,
12 grams of polyporus lucidus, 12 grams of wild chrysanthemum, small blood rise 12 grams, 11 grams of Cortex Eucommiae, 10 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 5 times of amount water decoct 2 hours, filtration, the
Secondary plus 3 times of amount water decoct 0.5 hour, and filtration, twice decocting liquid merging staticly settles 24 hours, take supernatant, are concentrated under reduced pressure into
The clear cream that relative density is 1.25 at 60 DEG C, is dried to dried cream powder.
Embodiment 4
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 15 grams of Herba Epimedii, 18 grams of the horsewhip tip,
12 grams of polyporus lucidus, 12 grams of wild chrysanthemum, small blood rise 12 grams, 10 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 6 times of amount water decoct 1 hour, filtration, the
Secondary plus 2 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 24 hours, take supernatant, are concentrated under reduced pressure into 60
DEG C when relative density be 1.18 clear cream, be dried to dried cream powder.
Embodiment 5
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of the present embodiment include: 18 grams of Herba Epimedii, 20 grams of the horsewhip tip,
15 grams of polyporus lucidus, 14 grams of wild chrysanthemum, small blood rise 10 grams, 15 grams of Cortex Eucommiae, 14 grams of semen plantaginis.
The preparation method of the Chinese medicine composition of the present embodiment the following steps are included:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 5 times of amount water decoct 1.5 hours, filtration,
For the second time plus 3 times of amount water decoct 1 hour, and filtration, twice decocting liquid merging staticly settles 20 hours, takes supernatant, is concentrated under reduced pressure into
The clear cream that relative density is 1.15 at 60 DEG C, is dried to dried cream powder.
Embodiment 6
The oral solutions of the prevention and treatment diabetic retinopathy of the present embodiment, dried cream powder made from embodiment 1-5 is distinguished
It is dissolved with water, sucrose and potassium sorbate, encapsulating is then added, oral solutions are made in sterilizing.
Embodiment 7
The present embodiment prevention and treatment diabetic retinopathy granule, by dried cream powder made from embodiment 1-5 respectively with
Mannitol carries out ingredient, and granule is made according to the method for conventional Chinese materia medica preparation.
Embodiment 8
The tablet of the prevention and treatment diabetic retinopathy of the present embodiment, respectively and firmly by dried cream powder made from embodiment 1-5
Fatty acid magnesium carries out ingredient, and tablet is made according to the method for conventional Chinese materia medica preparation.
Embodiment 9
The capsule of the prevention and treatment diabetic retinopathy of the present embodiment, by dried cream powder made from embodiment 1-5, according to normal
Capsule is made in the method for rule Chinese materia medica preparation.
Comparative example 1
This comparative example prevention and treatment diabetic retinopathy Chinese medicine composition the difference from embodiment 1 is that, this implementation
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of example includes: 16 grams of Radix Astragali, 14 grams of the horsewhip tip, 10 grams of polyporus lucidus, mother chrysanthemum
Spend 13 grams, small blood rise 10 grams, 13 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
Comparative example 2
This comparative example prevention and treatment diabetic retinopathy Chinese medicine composition the difference from embodiment 1 is that, this implementation
The Chinese medicine composition of the prevention and treatment diabetic retinopathy of example includes: 8 grams of Herba Epimedii, 14 grams of the horsewhip tip, 18 grams of polyporus lucidus, mother chrysanthemum
Spend 13 grams, small blood rise 10 grams, 13 grams of Cortex Eucommiae, 12 grams of semen plantaginis.
Test case
One, in order to illustrate the Chinese medicine composition of the embodiment of the present invention to the preventive and therapeutic effect of diabetic retinopathy, this hair
It is bright to have carried out following zoopery.
Experimental animal: SD rat (SPF grades, male), weight 180-220g.Standard feed is fed, feeding environment: temperature
18-20 DEG C, humidity 50-55%, lighting hours 12h, day alternates with night.
Experimental group: SD rat is randomly divided into Normal group (5) and modeling group (80).Modeling group Rat Fast
12 hours, through abdominal cavity one injection streptozotocin 50mg/kg, rear molding venous blood sampling surveyed non-fasting blood-glucose within 3 days, and fasting blood-glucose is dense
When degree is greater than 16.7mmol/L (Johnson & Johnson's blood glucose meter is surveyed), i.e. modeling success, Normal group injects isometric physiological saline
As control.Blood glucose is still not less than this 68 horizontal diabetes rat and is divided into test group 1-5 according to blood glucose level pairing after 1 week
(every group of 9 rats), control group 1-2 (every group of 9 rats) and model control group (5).
Start to be administered, medication are as follows:
Test group 1-5: carrying out stomach-filling using Chinese medicine composition made from 1-5 of the embodiment of the present invention respectively, and dosage is
1.5g·kg-1·d-1.Control group 1-2: stomach-filling, dosage are carried out using Chinese medicine composition made from comparative example 1-2 of the present invention respectively
For 1.5gkg-1·d-1.Normal group and model control group: with physiological saline 10ml/kg stomach-filling.The above each group rat connects
Continuous administration 8 weeks.
Tonometry: 4 weeks and 8 weeks after modeling success, according to rat body weight intraperitoneal injection anesthetic yellow Jackets
(50mg/kg) measures the intraocular pressure of each rat after rat anesthesia using Tonolab tonometer.Test result is shown in Table 1.
Table 1
| Group | 4 weeks/mmHg | 8 weeks/mmHg |
| Blank control group | 8.6±0.7 | 8.7±0.7 |
| Test group 1 | 9.8±0.6 | 11.0±0.5 |
| Test group 2 | 9.7±0.6 | 10.8±0.6 |
| Test group 3 | 10.2±0.8 | 11.4±0.4 |
| Test group 4 | 10.0±0.7 | 11.2±0.5 |
| Test group 5 | 10.3±0.7 | 11.5±0.5 |
| Control group 1 | 10.9±0.6 | 16.6±0.4 |
| Control group 2 | 11.0±0.7 | 15.8±0.6 |
| Model control group | 11.7±0.5 | 18.2±0.4 |
The result shows that: relative to blank control group, over time, test group, control group, model control group rat
Intraocular pressure exists to be increased in various degree.Rats in test groups is below control group, and rats in test groups in treatment 4 weeks, 8 weeks intraocular pressures
Intraocular pressure amplification is significantly lower than control group, through examining two groups of comparing differences statistically significant (P < 0.05), illustrates implementation of the present invention
The Chinese medicine composition of example, which increases intraocular pressure caused by diabetic retinopathy, has significant therapeutic effect.
Fluorescein fundus angiography (FFA) checks: checking in the 4th and 8 week row rat eyes FFA.Rat anesthesia is adopted
With Tropicamide and Phenylephrine ocular fluid mydriasis, after 10% fluorescein sodium (2mg/kg) is injected intraperitoneally, confocal laser fundus fluorescence is being synchronized
Fundus tissue structure is detected under angiographic instrument.
FFA the result shows that, blank control group does not observe aneurysms, hard exudate, blood spots, velveteen spot and Macular
The pathological changes such as oedema.There is different degrees of microaneurysm, petechial hemorrhage in test group, control group, model control group, through than
Compared with rats in test groups microaneurysm quantity, fundus hemorrhage degree are lighter than control group.Each group rat retinal microvascular tumor quantity
Comparison result is shown in Table 2.
Table 2
The result shows that: relative to blank control group, over time, test group, control group, model control group rat
Retina microangioma quantity exists to be increased in various degree.Rats in test groups is in treatment 4 weeks, 8 weeks retina microangiomas
Quantity is less than control group, and has lower microaneurysm quantity increment rate, through examining two groups of comparing differences to have statistics meaning
Adopted (P < 0.05), it is micro- caused by diabetic retinopathy to illustrate that the Chinese medicine composition of the embodiment of the present invention can be treated effectively
Hemangioma.
Two, in order to verify therapeutic effect of the Chinese medicine composition to diabetic retinopathy of the embodiment of the present invention, this hair
It is bright to have carried out following clinical test.
1 general information
68 diagnosis of diabetic retinopathy patients for selecting this test of voluntary participation are included in standard: referring to " Chinese medicine
Clinical Researches of New Drugs guideline " diagnosis of diabetic retinopathy standard in (tentative).There is diabetic symptom, and in 1d
Plasma glucose concentration >=11.1mmol/L when any, or on an empty stomach after at least 8h, plasma glucose concentration >=7.0mmol/
Plasma glucose concentration >=11.1mmol/L of L or standard 75g dextrose tolerance test (OGTT) 2h.Diabetic retinopathy
Become staging scale: there were microaneurysm, small bleeding in I phase；II phase, there is hard exudate；There is the soft exudation of flocculence in III phase.Row
Except with the severe primaries such as angiocarpy, liver, kidney, hemopoietic system disease and mental patient, gestation, breast feeding women and have
Allergies person.All patients refuse to obey the drug that may influence to observe result with other during treatment.
Patient is randomly divided into 2 groups.Treatment group 34, wherein male 20, female 14；Age 20-68 years old, average (42.5
± 6.2) year；Course of disease 0.5-8, average (5.2 ± 1.8) year.Control group 34, male 18, female 16；It age 20-65 years old, puts down
(40.6 ± 5.5) year；Course of disease 0.5-9, average (6.0 ± 1.6) year.2 groups of patient's general information comparing differences are without statistics
Meaning (P > 0.05), is comparable.
2 treatment methods
Treatment group: the Chinese medicine composition of the embodiment of the present invention 2.1 dose is divided to two days and takes, and is taken for every natural gift early, middle and late 3 times.
Control group: calcium hydrophenyl sulfonate capsule takes orally, 0.5g/ times, 3 times/day.
3 criterions of therapeutical effect
It is effective: eyesight progress >=4 rows or eyesight progress >=1.0；Fundus oculi changes show retinal angiomatous number by (+++)
It reduces to (++), or is reduced by (++) to (+), or by (+) to disappearance；Fundus hemorrhage amount is reduced by (+++) to (+), or by (+
+) extremely disappear；Seepage discharge is reduced by (+++) to (++), or is reduced by (++) to (+), or by (+) to disappearance；Microaneurysm number,
Amount of bleeding, seepage discharge change have 2 and 2 or more indexs to reach requirement.
It is effective: eyesight progress >=2 rows；Fundus oculi changes show that retinal angiomatous number is reduced by (+++) to (++), or by (+
+) reduce to (+), or by (+) to disappearance；Fundus hemorrhage amount is reduced by (+++) to (+), or by (++) to disappearance；Seepage discharge by
(+++) is reduced to (++), or is reduced by (++) to (+), or by (+) to disappearance；Microaneurysm number, amount of bleeding, seepage discharge change
There is 1 index to reach requirement.
Invalid: indices are not up to the above standard.
Deteriorate: 2 row of eyesight room for manoeuvre >；Fluorescence fundus angiography inspection shows that retina blood capillary expands without perfusion area
Greatly, macular edema aggravates, and vascular leakage increases.
4 results
2 groups continuously treatment counted curative effect after 3 months, the results are shown in Table 3.
Table 3
| Group | Number of cases | It is effective | Effectively | In vain | Deteriorate | Total effective rate |
| Treatment group | 34 | 20 | 11 | 2 | 1 | 91.18 |
| Control group | 34 | 10 | 12 | 4 | 8 | 64.71 |
The result shows that: treatment group's patient's total effective rate is 91.18%, and control group patient's total effective rate is 64.71%, through examining
It is statistically significant (P < 0.05) to test two groups of comparing differences, illustrates the Chinese medicine composition of the embodiment of the present invention to diabetes view
The therapeutic effect of film lesion is better than existing drug calcium hydrophenyl sulfonate capsule.
To treatment group, blood urine routine, liver function index of correlation and renal function index of correlation are supervised during treatment simultaneously
It surveys, it is no abnormal.Further, effective to treatment group and effective patient do not recur up to follow-up in 2 years
Situation.
Although above having used general explanation and specific embodiment, the present invention is described in detail, at this
On the basis of invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore,
These modifications or improvements without departing from theon the basis of the spirit of the present invention are fallen within the scope of the claimed invention.
Claims (5)
1. a kind of Chinese medicine composition for preventing and treating diabetic retinopathy, which is characterized in that the Chinese medicine composition is by following heavy
The raw material of amount number is made:
10-20 parts of Herba Epimedii, 10-20 parts of the horsewhip tip, 10-15 parts of polyporus lucidus, 10-15 parts of wild chrysanthemum, small blood rise 10-15 parts, Du
It is 10-15 parts secondary, 10-15 parts of semen plantaginis.
2. the Chinese medicine composition of prevention and treatment diabetic retinopathy according to claim 1, which is characterized in that the Chinese medicine
Composition is prepared from the following raw materials in parts by weight:
18 parts of Herba Epimedii, 16 parts of the horsewhip tip, 13 parts of polyporus lucidus, 13 parts of wild chrysanthemum, small blood rise 12 parts, 12 parts of Cortex Eucommiae, semen plantaginis 12
Part.
3. a kind of preparation method of the Chinese medicine composition of prevention and treatment diabetic retinopathy of any of claims 1 or 2, feature
It is, the described method comprises the following steps:
It gets each raw material ready according to the weight ratio, adds water to cook twice, for the first time plus 4-6 times is measured water and decocted 1-2 hours, filtration, the
Secondary to add 2-4 times to measure water decoction 0.5-1 hours, filtration, decocting liquid merging twice staticly settles 18-24 hours, takes supernatant, depressurizes
Relative density is the clear cream of 1.15-1.25 when being concentrated into 60 DEG C, is dried to dried cream powder.
4. a kind of Chinese materia medica preparation for preventing and treating diabetic retinopathy, which is characterized in that the Chinese materia medica preparation by claim 1 or
Chinese medicine composition made from Chinese medicine composition described in 2 or method as claimed in claim 3 and pharmaceutically acceptable auxiliary material system
At.
5. the Chinese materia medica preparation of prevention and treatment diabetic retinopathy according to claim 4, which is characterized in that the preparation mouth
Take liquor, granule, tablet, any in capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910407722.1A CN109966349A (en) | 2019-05-16 | 2019-05-16 | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910407722.1A CN109966349A (en) | 2019-05-16 | 2019-05-16 | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109966349A true CN109966349A (en) | 2019-07-05 |
Family
ID=67073713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910407722.1A Pending CN109966349A (en) | 2019-05-16 | 2019-05-16 | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109966349A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247542A (en) * | 2010-12-23 | 2011-11-23 | 陈玉堂 | Medicine for treating diabetes and kidney disease, cataract and other diabetic complications |
| CN103120767A (en) * | 2013-03-21 | 2013-05-29 | 王钢柱 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
| CN104306579A (en) * | 2014-11-03 | 2015-01-28 | 南京市中医药 | Traditional Chinese medicine for treating diabetic retinopathy of yin deficiency and blood stagnation as well as preparation method and application thereof |
| CN104435487A (en) * | 2014-12-06 | 2015-03-25 | 周连才 | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof |
-
2019
- 2019-05-16 CN CN201910407722.1A patent/CN109966349A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247542A (en) * | 2010-12-23 | 2011-11-23 | 陈玉堂 | Medicine for treating diabetes and kidney disease, cataract and other diabetic complications |
| CN103120767A (en) * | 2013-03-21 | 2013-05-29 | 王钢柱 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
| CN104306579A (en) * | 2014-11-03 | 2015-01-28 | 南京市中医药 | Traditional Chinese medicine for treating diabetic retinopathy of yin deficiency and blood stagnation as well as preparation method and application thereof |
| CN104435487A (en) * | 2014-12-06 | 2015-03-25 | 周连才 | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 高天舒 等: "《实用中医内分泌病学》", 28 February 2018, 辽宁科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kapp et al. | Limitations of high dose intra-arterial 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas | |
| CN103845418B (en) | A kind of Chinese medicine composition for the treatment of retinal hemorrhage and uses thereof | |
| CN102813666B (en) | The application of arasaponin R1 in the medicine of control neuro-ophthalmic disease | |
| WO2012079419A1 (en) | Pharmaceutical composition for treating macular degeneration | |
| CN103565801B (en) | For treating compositions and the said composition application in treatment ocular disease of eyeground macular edema | |
| CN109966349A (en) | A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN114588236B (en) | Use of a composition in the preparation of a medicament | |
| CN108338980A (en) | Purposes of the chlorogenic acid in the drug for preparing prevention inflammation of eye section | |
| CN104840941B (en) | The application of vascular study polypeptide with integrin compatibility and binding ability and matrix metalloproteinase rejection ability | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN112336833A (en) | A Chinese medicinal composition for treating hemorrhagic eye diseases, and its preparation method | |
| CN106389948A (en) | Traditional Chinese medicine composition for effectively alleviating lumbar pain caused by kidney deficiency | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN108210683A (en) | A kind of pharmaceutical composition for treating glaucoma | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN103393757B (en) | Traditional Chinese medicine decoction for treating radioactive brain damage | |
| CN101390973A (en) | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction | |
| CN107714709A (en) | Otoginsenoside and its salt are preparing the purposes in treating cataract medicine | |
| CN110934980B (en) | Traditional Chinese medicine formula and application thereof | |
| CN1132610C (en) | Chinese medicine for treating diabetes and neurovascular lesion of both feet and its preparing process | |
| CN100500192C (en) | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN104587094A (en) | Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition | |
| CN106177331A (en) | A kind of Chinese medicine treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |
|
| RJ01 | Rejection of invention patent application after publication |